Italian Journal of Dermatology and Venereology最新文献

Background: Social media has transformed medical communication, providing dermatologists with opportunities for public education, professional visibility, and patient engagement. However, ethical and professional concerns arise due to the lack of dermatology-specific guidelines in Italy. While the National Federation of Orders of Physicians and Dentists (FNOMCeO) offers general recommendations, no targeted framework exists to regulate dermatologists' digital presence.

Methods: During the 32nd Annual AIDA Congress in May 2024, a working group of 23 dermatologists with active online engagement was formed. Existing ethical frameworks, including the Code of Medical Ethics, were reviewed to identify regulatory gaps. A core team drafted 12 statements, which were refined through a structured discussion and a vote to reach consensus.

Results: The working group developed 12 best practice statements covering key aspects of ethical online engagement, including responsible social media use, conflict-of-interest disclosures, adherence to scientific evidence, patient privacy, and the fight against misinformation. These statements establish clear principles to guide dermatologists in their digital communication.

Conclusions: This is the first dermatology-specific digital communication consensus in Italy, addressing an urgent need for ethical regulation. These recommendations provide a structured framework for dermatologists, ensuring responsible online engagement while maximizing public health impact. Further regulatory efforts are essential to maintain high professional and ethical standards in the digital era.

Hair loss in both men and women significantly impact quality of life and often has modest treatment outcomes. Recently, microtrauma, which involves small, intentional skin injuries, has emerged as a promising method to stimulate hair growth through immunomodulation in non-scarring alopecias. This review explores the pathogenesis of hair loss, the mechanisms behind microtrauma, various methods of inducing it, and their efficacy in treating non-scarring alopecia. Hair follicles undergo cyclic phases of growth, regression, and rest, influenced by microenvironmental factors, including immune cells. Procedures utilizing microtrauma can promote hair regrowth by manipulating immune cells through wound healing responses, increasing growth factor release, and enhancing blood circulation. Examples of microtrauma include microneedling, fractional and non-fractional lasers, contact immunotherapy, low-level laser therapy (LLLT), and platelet-rich plasma (PRP) injections. Microneedling promotes stem cell activation and the expression of hair growth-related genes. Iontophoresis enhances drug delivery. Lasers induce controlled tissue injury leading to regeneration that may promote transitions in hair growth phases. Photobiomodulation may stimulate cellular activity and prolong growth phases. Contact immunotherapy induces allergic immune responses that promote hair regrowth in alopecia areata, while PRP expedites wound healing and tissue restoration. In androgenetic alopecia, microneedling, lasers, LLLT, and PRP have shown efficacy in increasing hair density and thickness. For alopecia areata, contact immunotherapy, and combination therapies involving microneedling and lasers have demonstrated positive outcomes. Limited studies on telogen effluvium suggest that microneedling and PRP can improve hair density. Microtrauma-based treatments offer promising strategies for hair regeneration. Continued research is necessary to enhance therapeutic options for non-scarring alopecia.

Background: Bruton's Tyrosine Kinase Inhibitors (BTKIs) and mogamulizumab have revolutionized the treatment of hematologic malignancies, yet they are frequently associated with dermatologic adverse events (dAEs) that can impact patient quality of life and adherence. The aim is to evaluate the incidence, clinical features, and management of dAEs associated with BTKIs and mogamulizumab across multiple Italian dermatology centers.

Methods: We conducted a retrospective, multicenter study involving 80 patients treated with BTKIs or mogamulizumab from January to December 2024. Patients were stratified into three cohorts: mogamulizumab (MOG), ibrutinib (IBR), and other BTKIs. dAEs were assessed for type, location, severity (CTCAE v5.0), duration, and treatment outcomes.

Results: Eczema-like rashes were most frequent in BTKI-treated patients (43.2% in IBR; 22.2% in other BTKIs), while mogamulizumab was primarily associated with morbilliform rashes (36%). The mean duration of dAEs was under six months across all cohorts, with most cases graded as mild. Topical corticosteroids and emollients were the mainstay of treatment. Remission rates were 64% (MOG), 89.2% (IBR), and 83.3% (other BTKIs), with few cases of progression.

Conclusions: dAEs are common but manageable side effects of BTKIs and mogamulizumab. Dermatologic surveillance and early treatment are crucial for optimizing patient outcomes. Multidisciplinary collaboration is essential to prevent misdiagnosis and treatment interruptions, especially in cases of mogamulizumab-associated rash.

The 2023 American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) antiphospholipid syndrome (APS) criteria represent a significant stride forward in the holistic understanding of APS, emphasizing the role of interdisciplinary approaches in the management of this complex autoimmune condition. For dermatologists, these criteria reinforce the importance of recognizing cutaneous manifestations as integral components of the APS management framework. By bridging the gap between dermatologic and systemic observations, dermatologists can play a pivotal role in the early detection and management of APS, ultimately contributing to improved patient outcomes. As the field progresses, continued collaboration between dermatology and rheumatology will be essential in refining classification criteria and enhancing the quality of care for patients with APS.